Sabby Management’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Sabby Management’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-658	Closed	-$109K	–	228
2017 Q4	$109K	Buy	+658	New	+$1.13K	0.01%	133

Other funds holding ANTH

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Sabby Management's ANTH Position: Q4 2017 in Review

Sabby Management sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q4 2017, closing a stake of 52,046 shares — an estimated $89.6K sold.

Sabby Management first reported a position in ANTH in Q2 2013 and held it in 12 quarters. The position peaked at $7.07M in Q2 2013. 37 funds tracked by Wall St. Rank hold ANTH as of Q4 2017.

Sabby Management reported no remaining Anthera Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Sabby Management sold 52,046 Anthera Pharmaceuticals, Inc. shares in Q4 2017, an estimated $89.6K.
Sabby Management first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2013 and held it in 12 quarters.
Sabby Management's Anthera Pharmaceuticals, Inc. position peaked at $7.07M in Q2 2013.
37 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q4 2017.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.